Вы находитесь на странице: 1из 51

,

:
/

..

2012



III/IV
Gd
/


:

;
, ;
(SUV,
);
,
,
;

;
,
.

/ ;
/

(, )

:
T
18

F-

Ga

DOTATOC

18

F-
18
GLUT 1, 3
F-MISO
11
hSST 2,3,5
C-

18
F-

O -
11

18
F-

68

11

82

Rb ,

13

N-

18

F-

FLT(

18F-
,

.

:
18
F--

( /
)
()
/ = 0,8 0,9

WHO III/IV
WHO I-II

(: )

,


, .

.

.

.
.

.
(3-8
)

, .



24

- .

.

:

,
,

, ,
. ,
, ,
X.


.
:
.


81-86%,
40-92%,
68-84%

I-IMT (),
123
I-IPA ()
()
18
F-FT,18F-2FT()
18
F-6-DOPA()
Aminosurentransport
()
123

2 :
Na2+ -

, (,
, )

Na2+ -
: L-

e (,
)

,
,

C-MET ()
()

11

11C-MET 70%
!

18F-

11C- 11C-

-T2

18F-

82Rb-


.
(=60 .). .

.

(=60
.). .

11-

100%,
60%,
82%

11-

Tsuyuguchi N, Sunada I, Iwai Y, Annals of Nuclear Medicine 2004. - Vol. 18. No. 4. - 291-296.

123

I-IMT-

3-[123I]Iod--Methyl-L-Tyrosin (IMT)

WHO III

L-Tyrosin

123

I-IMT

C-

11

123I-IMT-
11C-MET -
II

123

I-IMT

WHO III

18

F-

I-IMT

123


123I-IMT
,

,
I-IMT

123

II

III (IV)

123

I-IMT

III

PNET

N = 22

123I-IMT
81%
(n = 3) <13 .

WHO III

123

I-IMT-:

I-IMT-:

123

F-- 123I-IMT :

18

WHO II ()

n=25
I-IMT

123

AUC: 0,96
IMT = 1,62
1

., .,

95 %, 100%, 96%
(0 , 1 , 6 , 18 )

H-M

AUC
Cho/Cr: 0,83

89 %, 83%, 88%
(1 , 2 , 6 , 17 )

NAA/Cr: 0,72
Cho/NAA: 0,90

Cho/Cr = 1,11 /
Cho/NAA = 1,17

I-IMT :

123

WHO II

, 2
T/B

T/B

1,87
1,41
40 Gy

1,54

()

1,32
1,52


, .
63-

SUVratio = 1.3

WHO III
57-

SUVratio = 4.2

MRI T2

MRI T1 + KM

CD 31

F- ()
18
F-6-DOPA
11
C-
18

CD 31

-T1 + Gd.

F- /M

18

F- /M

18

Stockhammer F, Plotkin M et al. J Neurooncol 2008

WHO III

F--:

123I-IMT
18

:
5-7 . vs. 12-13 .
/ ( 1,3)

( )

18
F--

123
I-IMT-

F--:

11
18

C-methionine

11

18

F-

K.J. Langen, . Jlich

[11]
[18F], 18F-
11-,

[Stber B. 2006]


18F- ?
K.J. Langen, . Jlich

M-T1-Gd

Fusion /

WHO III

M
T1-W+Gd




()
mod. Kleihues and Ohgaki 1997 Brain Pathol

:
F- vs.

18

K.J. Langen, . Jlich

18

F--

( 18F-)

45 c

II

HE 200x

III

:
18
F-- vs. M
(31 / 55 )

M+:

M:

M-T2

92.6%
89.7%
90.2%

: 96.3%
: 52.7 %
:
67.1%

TPF

0.5

M-T1

M-

M
M+
0

0.5
FPF

(Pauleit et al. 2004)

K.J. Langen, . Jlich

18F- 18F-


:
WHO III
32-
WHO II

-T1 + Gd.

-/M

-/M

11C-M 18F-

-
Pirotte et al. JNM 2004

MET-

WHO III

MET-

18F--

WHO III,
,


18F-
-

max 4.3

max 2.9



18F-




- 18F-
18F- WHO,

.

, 18F-

, 43 . 13 .


(GrII)

-
.
-
(2)

(?);
b- 18F-

(=1,8);
- 11C- -

(=2,3).

(Gr IV).



18F-

11C-

- .

(1)
,
.

=1,7
18F-

=2,5
11C-

=0,5

=1,2

(1) , .

.
18F-

18
11
F-
-

11

18F-FLT

FLT


FLT-

18F-FLT

Saga et al. Clin Nucl Med 2006


[18F]

[18F]

[18F]

18F-

Shankar Vallabhajosula, 2009

18F-

18F-
WHO III

De Grado et al., 2001

O-H20 vs. T2* M

15

T1-M

15

O-H20-

T2*-MRT
(BOLD )

Dr. L. Ldemann

:
( )
:



( )





SSRT 2
111In-ctreotid(ntreotid):
,


Asgharian B et al. Clinical Cancer Research 2004; 10: 869-880

/T 68Ga-DOTATOC


Henze et al. Int J Radiat Oncol Biol Phys. 2006;65:222-227

Ga-DOTATOC /:

68

Ga-DOTATOC:

68

Potential Impact of 68Ga-DOTATOC PET/CT on Planning the


Stereotactic Radiotherapy in Meningiomas
Nyuyki Fonyuy, Michail Plotkin, Reinhold Graf, Timm Dennecke, Lilli Geworski,
Bernd Hamm, Reinhard Wurm

43 (26 , 17 , 25- 71, . 57)


35 /
compositve volume (GTVCT+MRT) 42/43

68Ga-DOTATOC PET/CT

40/42 68Ga-DOTATOC

GTVPET+CT+MRT GTVCT+MRT 69%

19 , 9

1
59-
(WHO II).

1+Gd

Ga-DOTATOC-/T

68

68

Ga-DOTATOC-/T

3
5

,

Gd

Оценить